Maravai LifeSciences Holdings Inc’s (MRVI) Stock: A -5.36% Simple Moving Average for the Past 20 Days

The stock of Maravai LifeSciences Holdings Inc (MRVI) has gone down by -13.68% for the week, with a -34.90% drop in the past month and a -43.54% drop in the past quarter. The volatility ratio for the week is 5.94%, and the volatility levels for the past 30 days are 8.57% for MRVI. The simple moving average for the past 20 days is -5.36% for MRVI’s stock, with a -36.86% simple moving average for the past 200 days.

Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?

Additionally, the 36-month beta value for MRVI is -0.08. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for MRVI is 117.54M and currently, short sellers hold a 5.92% ratio of that float. The average trading volume of MRVI on December 05, 2024 was 1.81M shares.

MRVI) stock’s latest price update

Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has plunge by -5.63relation to previous closing price of 5.41. Nevertheless, the company has seen a -13.68% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.

MRVI Trading at -25.53% from the 50-Day Moving Average

After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.78% of loss for the given period.

Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 5.94%, as shares sank -36.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.98% lower at present.

During the last 5 trading sessions, MRVI fell by -13.77%, which changed the moving average for the period of 200-days by -2.95% in comparison to the 20-day moving average, which settled at $5.40. In addition, Maravai LifeSciences Holdings Inc saw -21.98% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MRVI starting from DeFord John A, who purchase 17,500 shares at the price of $5.75 back on Nov 12 ’24. After this action, DeFord John A now owns 70,046 shares of Maravai LifeSciences Holdings Inc, valued at $100,625 using the latest closing price.

HULL CARL purchase 175,000 shares at $5.64 during a trade that took place back on Nov 11 ’24, which means that HULL CARL is holding 175,000 shares at $987,000 based on the most recent closing price.

Stock Fundamentals for MRVI

Current profitability levels for the company are sitting at:

  • -0.71 for the present operating margin
  • 0.44 for the gross margin

The net margin for Maravai LifeSciences Holdings Inc stands at -0.81. The total capital return value is set at -0.16. Equity return is now at value -51.98, with -12.67 for asset returns.

Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 1.51. The interest coverage ratio of the stock is -3.77.

Currently, EBITDA for the company is 712.41 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 2.58. The receivables turnover for the company is 9.59for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.74.

Conclusion

In conclusion, Maravai LifeSciences Holdings Inc (MRVI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts